Gufic Biosciences Limited · NSE:GUFICBIO
Gufic Biosciences — Q1 FY25 Earnings Presentation
34 slides from Gufic Biosciences's earnings presentation, Aug 14, 2024
Slide 1: Stock exchange filing cover letter
192/LG/SE/AUG/2024/GBSL August 14, 2024 To, To, BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra Kurla Complex, Dalal Street, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 509079 Scrip Symbol: GUFICBIO Subject: Investor Presenta
Slide 2: Delivering Care & Cure - Investor Presentation August 2024
Delivering Care & Cure Investor Presentation August 2024
Slide 3: Safe Harbor
Safe Harbor This presentation has been prepared by and is the sole responsibility of Gufic Biosc iences Limited (the “ Company”). By accessing this presentation, you are agreeing to be bound by the trailing restrictions . This prese ntation does not constitute or form part of any offer or invitation
Slide 4: Q1 FY25 Business & Financial Highlights
Q1 FY25 Business & Financial Highlights
Slide 5: Q1 FY25 Business Highlights
Q1 FY25 Business Highlights Indore Capex Update: The Indore capex expansion represents a transformative step for Gufic Biosciences, designed to more than double our manufacturing capacity. This strategic move is crucial for accommodating our growing order book and enhancing our production capabiliti
Slide 6: Q1 FY25 Business Highlights
Q1 FY25 Business Highlights Critical Care Division Domestic Business Breakup Our Critical Care division continues to fortify its position as a leader in the sector through strategic initiatives, innovative product offerings, and unwavering commitment to quality and patient care. Critical Care Divisi
Slide 7: Q1 FY25 Business Highlights
Q1 FY25 Business Highlights Global Representation at EUROASIA 2024: • Gufic proudly showcased its comprehensive range of antimicrobials at EUROASIA 2024, one of the most prestigious platforms in the healthcare sector. Our participation not only highlighted our product excellence but also reinforced
Slide 8: Q1 FY25 Business Highlights
Q1 FY25 Business Highlights New Initiatives and Market Expansion: • Launch of Dydro 20mg & 30mg SR Tablets: Introduce extended-release formulations of Dydrogesterone, making us one of the few Indian companies to offer this innovative drug delivery system. This development is expected to revolutioniz
Slide 9: Q1 FY25 Business Highlights
Q1 FY25 Business Highlights Aestherderm Divison The Aestherderm division continues to carve out a niche in the aesthetic dermatology market, particularly with our flagship product, Stunnox. This quarter, we've made substantial strides in advancing the market penetration and clinical understanding of
Slide 10: Q1 FY25 Business Highlights
Q1 FY25 Business Highlights Spark, Stellar & Healthcare Division As we progress into the new fiscal year, the Spark, Stellar & Healthcare Division at Gufic Biosciences continues to demonstrate substantial growth and innovation. Building on our successful strategies from the previous quarters, we've
Slide 11: Q1 FY25 Business Highlights
Q1 FY25 Business Highlights Sparsh The Sparsh Division continues to revolutionize the market with its direct-to-hospital distribution model. In in this model, we provide hospitals with more competitive pricing and better visibility of sales. This approach has positioned Sparsh as a leader in direct
Slide 12: Q1 FY25 Business Highlights
Q1 FY25 Business Highlights International Division New Product Registrations: • In Q1FY25, we successfully secured new product registrations in key international markets, further diversifying our global portfolio: o Lithuania: Vancomycin IBE 1000 mg and 500 mg powder for concentrate for solution for
Slide 13: Research & Development
Research & Development Update on R&D Update on Selvax • Peptides R&D: Paving the Way for In-house Critical • Positive Results from Mouse Studies: API Manufacturing: Our foray into peptides research and development aligns seamlessly with our broader • Selvax conducted comprehensive studies in mice us
Slide 14: Strategic Initiatives
Strategic Initiatives Strategic Initiatives that will further amplify growth over the next few years Increase in overall market and market share in Leverage new biological Botulinum Toxin range of Increase market share in technology platform to products through Commercialization of contract manufact
Slide 15: Profit & Loss Statement
Profit & Loss Statement Pa r t i c u l a rs ( i n R s . C r o re) Q1 FY25 Q4 FY24 Q1FY24 FY24 To ta l Rev e n u e 202.8 194.9 195.0 806.7 E B I T DA 37.0 35.1 36.4 148.1 E B I T DA M a r g i n % 18.2% 18.0% 18.6% 18.4% P ro f i t b efo re Ta x 28.1 27.1 28.1 115.7 P BT M a r g i n s % 13.9% 13.9% 14
Slide 16: Company Overview
Company Overview
Slide 17: About Gufic Biosciences
About Gufic Biosciences Research based Pharmaceutical Company recognized for its innovative, high quality Pharmaceuticals Nutraceuticals, Natural Herbal products One of the Largest Manufacturers of Lyophilized Injections in India with a wide range of products in various therapy areas BUSINESS STRUCT
Slide 18: World Class Manufacturing Infrastructure
World Class Manufacturing Infrastructure Unit - I at Navsari Unit - II at Navsari Gufic - Belgaum Botulinum Toxin Facility Lyophilized Injectables Facility Natural Products Facility Lyophilized/Powder Injectables Facility Capability to manufacture Liposomal Amphotericin B and Depot Injections Natura
Slide 19: Upcoming World Class Manufacturing Infrastructure
Upcoming World Class Manufacturing Infrastructure Unit - III at Indore Penem Block UPDATE ON CAPEX Indore Lyophilized/Powder Injectables Dedicated facility for Penem Validation completed for two line, other 2 lines will be Facility Carbapenems (Lyophilized / Dry completed by September Capability to
Slide 20: Botulinum Toxin Facility
Botulinum Toxin Facility Gufic has built a state-of-the-art manufacturing facility for Botulinum Toxin in Navsari Gufic has partnered with Prime Bio, USA for manufacturing Botulinum Toxin API and formulation Gufic is equipped with all the necessary analytical testing procedures for safety and effica
Slide 21: Consolidating the Domestic Branded Business
Consolidating the Domestic Branded Business Products CRITICAL CARE INFERTILITY MASS SPECIALITY 100+ SKU’s Field Force: 250 Field Force: >150 Field Force: >180 200+ Therapy Areas: Antibacterial, Therapy Areas: Hormones, Therapy Areas: Anti Infectives, Antifungal, Pain Management, Recombinant Products
Slide 22: Expanding Creditability in CMO Business
Expanding Creditability in CMO Business Offer CMO services for India and 70+ 150+ Products Reliable CMO service for quality products over a Global Markets Companies across multiple therapy areas decade One of the Largest Supplier of Formulations Liposomal Doxycycline Tigecycline Gonadotropins Micafu
Slide 23: Expanding Geographical Reach
Expanding Geographical Reach 130+ Products registered globally (in 15+ countries) 150+ Products in pipeline for registration (in 30+ countries) CANADA | COSTA RICA | PANAMA | COLUMBIA | CHILE | LATVIA | LITHUANIA | BELARUS | GERMANY | AUSTRIA | PORTUGAL | MOROCCO ALGERIA | DOMINICAN REPUBLIC | VENEZ
Slide 24: Building API Capabilities
Building API Capabilities Special Facility dedicated to API Focused on developing non The categories of API’s infringing, novel, cost manufactured are effective and scalable antifungals, antibacterial, chemical process for APIs, anesthetics and Peptides and Cyclopeptides intermediates for antifungal
Slide 25: Strong Partnership & Licensing Deals
Strong Partnership & Licensing Deals Through our collaborations with global partners that are European leader in IV drug researching to expand the frontiers of pharma and delivery systems. Collaborated biotechnology, Gufic will be a technology bridge to the with Gufic to launch Dual future of health
Slide 26: Extensive Sales, Distribution and IT Infrastructure in India
Extensive Sales, Distribution IT Infrastructure in India 2 Central Warehouses Pan India Presence with a located in North Delhi and field force of 1,000+ West Bhiwandi IT Infrastructure Retail coverage of more than 23 Carrying & Forwarding (C&F) agents across India Integrated IT Systems with Sales 1,
Slide 27: Growth Levers
Growth Levers 1 2 3 INTERNATIONAL INDIA BUSINESS CMO BUSINESS BUSINESS • Consolidation of the Critical Care Infertility • Expand our presence in regulated • Scale up the manufacturing capacity business markets such as US EU • Entry into new therapy areas Dermatology - • Consolidation of the clients
Slide 28: Our Robust R&D and Clinical team to augment growth
Our Robust R&D and Clinical team to augment growth Research & Development (R&D) Clinical Team State-of-the-art R&D Facility in Navsari, Gujarat with expertise in Formulation Development Technology Transfer API Development Patents in various therapy areas Granted: 5 Filed/In-process of filling : 8 Ma
Slide 29: Historical Financials
Historical Financials
Slide 30: Historical Financials
Historical Financials Particulars (Rs. Crs.) FY24 FY23 FY22 FY21 FY20 FY19 Total Revenue 808.8 693.2 782.3 491.4 384.6 359.5 EBITDA 148.0 137.2 151.1 87.7 57.9 56.7 EBITDA Margin % 18.3% 19.8% 19.3% 17.8% 15.1% 15.8% Profit before Tax 115.7 106.7 126.8 57.7 30.1 40.2 PBT Margin % 14.3% 15.4% 16.2% 1
Slide 31: Historical Balance Sheet (Equity & Liabilities)
Historical Balance Sheet (Equity & Liabilities) EQUITY & LIABILITIES (Rs. Crs.) Mar-24 Mar-23 Mar-22 Mar-21 Mar-20 Mar-19 Equity Share Capital 10 9.7 9.7 9.7 9.7 7.8 Other Equity 522.5 338.1 259.4 163.7 119.6 67.6 Total Equity 532.5 347.8 269.1 173.4 129.3 75.3 Non-Current Liabilities Financial Liab
Slide 32: Historical Balance Sheet (Assets)
Historical Balance Sheet (Assets) ASSETS (Rs. Crs.) Mar-24 Mar-23 Mar-22 Mar-21 Mar-20 Mar-19 Non-Current Assets Property, plant and equipment 138.3 126.8 105.5 93.8 72.7 70.3 Intangible assets 5.6 0.7 0.6 0.4 0.6 0.4 Capital work-in-progress 307.1 169.6 40.9 13.4 30.6 9.6 Right of use assets 14.9 3
Slide 33: Historical Cash Flows
Historical Cash Flows Cash Flow Statement (Rs. Crs.) FY24 FY23 FY22 FY21 FY20 FY19 Net Profit Before Tax 115.7 106.7 126.9 57.7 30.1 35.3 Adjustments for: Non - Cash Items / Other Investment or 34.1 29.6 23.2 30.8 24.7 13.4 Financial Items Operating profit before working capital changes 149.8 136.4
Slide 34: Thank You
THANK YOU Company: Gufic Biosciences Limited CIN: L24100MH1984PLC033519 Mr. Avik Das – Investor Relations avik.das@guficbio.com Tel: +91 22 67261000